Payment overview · 2025
General Payments
$665.22
26 reported records · 13 companies
Healthcare provider profile · identity verified
Vincent Gregory Gonzaba, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1538192489
Verified facts
What the public records show
CMS Open Payments records show Vincent Gregory Gonzaba, MD received $665.22 in general payments during 2025 across 26 reported records.
Lilly USA, LLC accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.49 | 22.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.55 | 20.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.42 | 9.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $62.09 | 9.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.11 | 7.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.88 | 6.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.59 | 5.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.86 | 4.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $30.31 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.52 | 3.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.15 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.22 | 2.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $5.03 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $665.22 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $137.43 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.42 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $62.09 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $30.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.07 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11.06 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $5.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 776 | 235 |
| Metformin Hcl | Metformin Hcl | 565 | 173 |
| Losartan Potassium | Losartan Potassium | 492 | 152 |
| Lisinopril | Lisinopril | 395 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 99 |
| Tramadol Hcl | Tramadol Hcl | 237 | 52 |
| Alprazolam | Alprazolam | 228 | 46 |
| Gabapentin | Gabapentin | 228 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 73 |
| Simvastatin | Simvastatin | 210 | 58 |
| Omeprazole | Omeprazole | 208 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 25 |
| Ibuprofen | Ibuprofen | 203 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 192 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 185 | 63 |
| Glimepiride | Glimepiride | 183 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 45 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 176 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 45 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 154 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 46 |
| Trazodone Hcl | Trazodone Hcl | 139 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 43 |
| Carvedilol | Carvedilol | 121 | 43 |
| Meloxicam | Meloxicam | 115 | 39 |
| Ozempic | Semaglutide | 109 | 25 |
| Pregabalin | Pregabalin | 107 | 23 |
| Glipizide | Glipizide | 105 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 31 |
| Furosemide | Furosemide | 94 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 33 |
| Jardiance | Empagliflozin | 89 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 33 |
| Eliquis | Apixaban | 86 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Enalapril Maleate | Enalapril Maleate | 78 | 20 |
| Montelukast Sodium | Montelukast Sodium | 74 | 28 |
| Metformin Hcl Er | Metformin Hcl | 73 | 28 |
| Nifedipine Er | Nifedipine | 70 | 19 |
| Finasteride | Finasteride | 62 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | 15 |
| Januvia | Sitagliptin Phosphate | 51 | 15 |
| Sertraline Hcl | Sertraline Hcl | 51 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 15 |
| Donepezil Hcl | Donepezil Hcl | 48 | 13 |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Famotidine | Famotidine | 46 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Levemir Flexpen | Insulin Detemir | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 14 |
| Myrbetriq | Mirabegron | 40 | 17 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 21 |
| Allopurinol | Allopurinol | 35 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 18 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Alendronate Sodium | Alendronate Sodium | 33 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | 11 |
| Glipizide Er | Glipizide | 30 | 11 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 29 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $665.22 · 26 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, GEMTESA, Heplisav-B, JARDIANCE, JOURNAVX, KISUNLA, MOUNJARO, PREVNAR 20, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error